Abstract
Biopharmaceuticals and innovative therapeutic solutions offer treatments that are increasingly tailored to patient needs. Although biotechnology has produced health benefits, biopharmaceutical products require resources that governments had not planned or budgeted for in the appropriate time frame. As a result, economics has entered the healthcare arena without taking a number of important societal concerns into account. More specifically, several governments have introduced procedures to evaluate the cost-effectiveness of newly approved medicines. Unfortunately, patient access is not an equation of public budget figures, but an equation of government priorities. Therefore, this paper describes the limits of traditional pharmacoeconomic evaluations particularly when applied to innovative biopharmaceuticals and offers solutions to the questions they pose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
